B. Riley Securities Rates Nutex Health (NUTX) buy

B. Riley Securities maintains its buy rating on Nutex Health Inc. with a $290 price target, a 72.16% upside from the current price.

By EarningsIQ Research Desk · Published Jun 27, 2026, 3:03 AM EDT · Updated Jul 1, 2026, 4:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

B. Riley Securities rated Nutex Health Inc. ($NUTX) "buy" with a $290 price target on June 26, 2026.

Since the rating, $NUTX is up 16.3% after 1 week, down 10.6% after 1 month and up 11.8% to date (from the $166.40 close on Jun 26, 2026).

NUTX Nutex Health Inc.

$186.10 +25.58% year to date

Daily close · Oct 16, 2026

Key Points

B. Riley Securities reiterated its buy rating on Nutex Health Inc. (NUTX) on June 26, 2026, with a price target of $290.
B. Riley Securities's $290 price target implies 72.16% upside from Nutex Health Inc.'s ($NUTX) current $168.45 share price.
Nutex Health Inc. shares traded at $161.68 on Saturday, with a market cap of approximately $1.15 billion and a P/E ratio of 12.17.
Key insider purchases at Nutex Health include CEO Dr. Thomas Vo buying 75,747 shares on May 28, 2026.

Get $NUTX trade alerts by text

We text you when insiders, Congress or big funds trade $NUTX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nutex Health Inc. alert may contain errors. Disclosures

B. Riley Securities has reiterated its buy rating on Nutex Health Inc. (NasdaqCM: NUTX) with a price target of $290. This analyst action was announced on June 26, 2026, by Anderson Schock.

Analyst rating track record

B. Riley Securities vs. the S&P 500

YTD return +10.25% hypothetical

All-time return +52.14% S&P 500 +17.15%

vs. S&P 500 +34.99% ahead of the index

Hypothetical returns from B. Riley Securities's disclosed trades, not real profit or advice. How we model this.

Nutex Health Inc. Stock Down 19.3%

Shares of NasdaqCM:NUTX traded near $161.68 on Saturday. Nutex Health Inc. has a market cap of approximately $1.15 billion, a P/E ratio of 12.17, and a beta of 2.057. The stock's 52-week range spans from $77.21 to $193.07. Its 50-day moving average is $129.59, and the 200-day moving average is $124.68. The company shows a strong financial position with a current ratio of 3.14 and a quick ratio of 3.0, while its debt-to-equity ratio stands at 78.97.

12-month forecast

$NUTX price target

Nutex Health Inc. daily closes and this analyst's $290 target. Not advice.

Recent Earnings

Nutex Health Inc. reported revenue of about $880 million, showing a 2.2% growth. The company's net margin is 10.95%, with a return on equity of 53.65%. The next earnings report is expected on July 30, 2026.

Insider Buying and Selling at Nutex Health Inc.

Recent insider transactions at Nutex Health include CEO Dr. Thomas Vo purchasing 75,747 shares on May 28, 2026. Other notable buys include Kelvin Spears acquiring 2,519 shares on June 4, 2026, and Cheryl Yvonne Grenas, Frank Jaumot, Michael Lee Reed, and Scott Saunders each buying 823 shares on April 23, 2026.

Analysts Set New Price Targets

On June 26, 2026, B. Riley Securities reiterated its buy rating on Nutex Health with a $290 price target. Earlier, on June 2, 2026, Lake Street initiated coverage with a buy rating and a $235 target. The consensus among analysts is a buy rating, with a mean target price of $235.50 based on four opinions.

About Nutex Health Inc.

Nutex Health Inc., based in Houston, Texas, operates in the healthcare sector, specifically in medical care facilities. The company manages a network of micro hospitals and specialty hospitals, providing services such as emergency care and imaging. Nutex also offers population health management services and operates a real estate segment that owns hospital properties. Founded in 2011, Nutex Health is led by CEO Dr. Thomas T. Vo.

Bottom Line

B. Riley Securities' reaffirmation of its buy rating on Nutex Health Inc. with a $290 price target underscores the firm's confidence in the company's growth potential. Investors closely monitor such analyst ratings and insider transactions for insights into the company's prospects. As always, remember that analyst ratings and 13F filings are backward-looking and may not reflect the current market conditions.